Edition:
United Kingdom

Evotec AG (EVTG.DE)

EVTG.DE on Xetra

19.83EUR
11:17am BST
Change (% chg)

€0.34 (+1.74%)
Prev Close
€19.49
Open
€20.05
Day's High
€20.15
Day's Low
€19.72
Volume
568,517
Avg. Vol
1,082,660
52-wk High
€22.50
52-wk Low
€11.52

Latest Key Developments (Source: Significant Developments)

Evotec H1 Revenue Rises By 67 Pct
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Evotec AG ::H1 REVENUE ROSE 67 PERCENT TO 173.8 MILLION EUR.67% INCREASE IN GROUP REVENUES, 47% INCREASE IN ADJUSTED GROUP EBITDA.GROUP REVENUES: 67% INCREASE TO EUR 173.8 M (H1 2017: EUR 104.3 M).GUIDANCE ON GROUP REVENUES - GROWTH OF >30% CONFIRMED.GUIDANCE ON ADJUSTED GROUP EBITDA - GROWTH OF APPROX. 30% CONFIRMED.GUIDANCE ON RESEARCH AND DEVELOPMENT EXPENSES INCREASED - RESEARCH AND DEVELOPMENT EXPENSES FOR 2018 WILL INCREASE TO EUR 35-45 M.  Full Article

Evotec Repays Half of 140 Mln Euro Acquisition Loan
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Evotec AG ::DGAP-NEWS: EVOTEC REPAYS 50% OF EUR 140 M ACQUISITION LOAN.EXPECTS REPAYMENT TO SHOW A SIGNIFICANTLY POSITIVE EFFECT ON NET DEBT RATIO IN COMPANY'S RESULTS.  Full Article

Evotec AG Will Be Renamed Evotec SE
Wednesday, 20 Jun 2018 

June 20 (Reuters) - EVOTEC AG ::WILL BE RENAMED EVOTEC SE.  Full Article

Evotec And Celgene Enter Into Strategic Oncology Partnership
Monday, 21 May 2018 

May 21 (Reuters) - Evotec Ag ::DGAP-ADHOC: EVOTEC AND CELGENE ENTER INTO STRATEGIC ONCOLOGY PARTNERSHIP.UNDER TERMS OF AGREEMENT, EVOTEC WILL RECEIVE AN UPFRONT PAYMENT OF $65 MILLION.CELGENE RECEIVES EXCLUSIVE OPT-IN RIGHTS TO LICENSE WORLDWIDE RIGHTS TO ALL PROGRAMMES DEVELOPED WITHIN THIS COLLABORATION.EVOTEC MAY BE ELIGIBLE TO RECEIVE SIGNIFICANT MILESTONE PAYMENTS AS WELL AS TIERED ROYALTIES ON EACH LICENSED PROGRAMME.  Full Article

Evotec Affirms Guidance After Q1 Results
Wednesday, 9 May 2018 

May 9 (Reuters) - Evotec AG ::DGAP-NEWS: EVOTEC REPORTS FIRST QUARTER 2018 RESULTS AND PROVIDES CORPORATE UPDATE.Q1 REVENUE ROSE 55 PERCENT TO 79 MILLION EUR.55% INCREASE IN GROUP REVENUES.Q1 GROUP REVENUES: 55% INCREASE TO EUR 79.0 M.Q1 ADJUSTED GROUP EBITDA UP 4% TO EUR 14.0 M.FINANCIAL GUIDANCE 2018 CONFIRMED.  Full Article

Evotec, Apeiron Biologics receive milestone payment from Sanofi
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Evotec Ag ::SAYS ‍EVOTEC AND APEIRON ACHIEVE FIRST MILESTONE IN IMMUNO-ONCOLOGY ALLIANCE WITH SANOFI​.SAYS ‍MILESTONE PAYMENT OF EUR 3 M WILL BE SPLIT EQUALLY BETWEEN TWO BIOTECH COMPANIES​.SAYS ‍SUCCESS PAYMENT WAS TRIGGERED WHEN PARTNERS SUCCESSFULLY ADVANCED AN UNDISCLOSED, NOVEL IMMUNO-ONCOLOGY SMALL MOLECULE INTO LATE-STAGE PRE-CLINICAL DEVELOPMENT​.SAYS ‍UNDER ALLIANCE, THREE COMPANIES WORK TOGETHER TO IDENTIFY SMALL MOLECULE LEADS AND TARGETS FOR NEXT-GENERATION THERAPIES IN IMMUNO-ONCOLOGY​.  Full Article

Evotec affirms guidance after 9-month core profit jump
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Evotec Ag :9M revenue rose 42 percent to 170.9 million eur.‍9M adjusted group EBITDA up 28% to eur 39.3 m (9m 2016: eur 30.6 m)​.Says ‍guidance 2017 confirmed​.  Full Article

Germany's Evotec to acquire U.S.-based Aptuit for 256 mln euros
Sunday, 30 Jul 2017 

July 30 (Reuters) - Evotec AG :Evotec to acquire Aptuit, expanding leadership in external innovation.Consideration of about 256 million euros to be paid in cash from Evotec's balance sheet and through debt financing at highly attractive terms.  Full Article

Evotec, Carrick Therapeutics agree strategic alliance
Tuesday, 4 Oct 2016 

Evotec AG : Evotec and Carrick Therapeutics build strategic alliance . Evotec contributes $6 million to Carrick's $95 million funding round through a top-class global investor consortium .Evotec's financial guidance for 2016, also with regard to liquidity, remains unchanged.  Full Article

Evotec, Bayer to develop new treatments to fight kidney diseases
Wednesday, 21 Sep 2016 

Evotec AG : Says goal is development of multiple clinical candidates for treatment of kidney diseases such as chronic kidney disease in diabetes patients . Says partners will share responsibilities during pre-clinical development of potential clinical candidates . Says will receive a minimum of eur 14 m over contract period including research payments and an undisclosed licence fee . Says is eligible to receive pre-clinical, clinical and sales milestones of potentially over eur 300 m as well as tiered royalties of up to low double-digit percentage of net sales .Says evotec and bayer partner to develop new treatments to fight kidney diseases.  Full Article

German stocks - Factors to watch on August 9

FRANKFURT/BERLIN, Aug 9 The following are some of the factors that may move German stocks on Thursday: